Hosted on MSN15d
Monoclonal antibody significantly reduces nasal polyps and need for surgery in Phase 3 clinical trialA decision to proceed with nasal polyp surgery was recorded in just 0.5% of tezepelumab-treated patients compared to 22.1% in the placebo group (hazard ratio, 0.02). Systemic glucocorticoid use ...
Tezepelumab reduced the size of nasal polyps and the severity of nasal ... who received standard care treatment with intranasal glucocorticoids and were randomly assigned to receive either a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results